Literature DB >> 23307936

Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase.

Robert B Couch1, Robert L Atmar, Luis M Franco, John M Quarles, Janet Wells, Nancy Arden, Diane Niño, John W Belmont.   

Abstract

BACKGROUND: Serum antibody to the hemagglutinin (HA) of influenza viruses is a correlate and predictor of immunity to influenza in humans; the relative values of other correlates are uncertain.
METHODS: Serum and nasal secretions (NS) were collected in fall and spring of 2009-2011 from healthy adults who were monitored for acute respiratory illness (ARI). Serum samples were tested for hemagglutination-inhibition (HAI) antibody increase and secretions for virus if ill; enrollment sera were also tested for neuraminidase-inhibiting (NI) antibody and NS for neutralizing (neut), NI, immunoglobulin A (IgA), and immunoglobulin G (IgG) anti-HA antibody.
RESULTS: Serum anti-HA and anti-neuraminidase (NA) antibody titers to 2009(H1N1) pandemic influenza virus (pH1N1) correlated with titers in NS (including IgA and IgG antibody). Increasing anti-HA and anti-NA titers in serum and NS tests all correlated with reducing infection and infection-associated illness. Multivariate analyses indicated serum HAI and NI each independently predicted immunity to infection and infection-associated illness. Only serum NI independently predicted reduced illness among infected subjects.
CONCLUSIONS: Increasing anti-HA and NA antibody in serum and secretions correlated with reducing pH1N1 influenza virus infection and illness in healthy young adults. Both anti-HA and anti-NA antibody are independent predictors of immunity to influenza; ensuring induction of both by vaccination is desirable.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23307936      PMCID: PMC3633450          DOI: 10.1093/infdis/jis935

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates.

Authors:  C R Lambré; H Terzidis; A Greffard; R G Webster
Journal:  J Immunol Methods       Date:  1990-12-31       Impact factor: 2.303

Review 2.  Immune responses to influenza virus in the mouse, and their role in control of the infection.

Authors:  J L Virelizier; A C Allison; G C Schild
Journal:  Br Med Bull       Date:  1979-01       Impact factor: 4.291

3.  Induction of partial immunity to influenza by a neuraminidase-specific vaccine.

Authors:  R B Couch; J A Kasel; J L Gerin; J L Schulman; E D Kilbourne
Journal:  J Infect Dis       Date:  1974-04       Impact factor: 5.226

4.  Neutralizing and hemagglutination-inhibiting activity of nasal secretions following experimental human infection with A2 influenza virus.

Authors:  R H Alford; R D Rossen; W T Butler; J A Kasel
Journal:  J Immunol       Date:  1967-04       Impact factor: 5.422

5.  Revised (1972-1973) bivalent influenza vaccine. Serum and nasal antibody responses to parenteral vaccination.

Authors:  R P Wenzel; J O Hendley; M A Sande; J M Gwaltney
Journal:  JAMA       Date:  1973-10-22       Impact factor: 56.272

6.  Association of serum anti-neuraminidase antibody with resistance to influenza in man.

Authors:  B R Murphy; J A Kasel; R M Chanock
Journal:  N Engl J Med       Date:  1972-06-22       Impact factor: 91.245

Review 7.  An overview of serum antibody responses to influenza virus antigens.

Authors:  R B Couch
Journal:  Dev Biol (Basel)       Date:  2003

8.  Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines.

Authors:  B R Murphy; D L Nelson; P F Wright; E L Tierney; M A Phelan; R M Chanock
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

9.  High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults.

Authors:  W A Keitel; R B Couch; T R Cate; K R Hess; B Baxter; J M Quarles; R L Atmar; H R Six
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

10.  Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement.

Authors:  A L Frank; J Puck; B J Hughes; T R Cate
Journal:  J Clin Microbiol       Date:  1980-09       Impact factor: 5.948

View more
  113 in total

1.  Characterization of antibody and memory T-cell response in H7N9 survivors: a cross-sectional analysis.

Authors:  M-J Ma; X-X Wang; M-N Wu; X-J Wang; C-J Bao; H-J Zhang; Y Yang; K Xu; G-L Wang; M Zhao; W Cheng; W-J Chen; W-H Zhang; L-Q Fang; W J Liu; E-F Chen; W-C Cao
Journal:  Clin Microbiol Infect       Date:  2019-06-20       Impact factor: 8.067

2.  Infectious Middle East Respiratory Syndrome Coronavirus Excretion and Serotype Variability Based on Live Virus Isolates from Patients in Saudi Arabia.

Authors:  Doreen Muth; Victor M Corman; Benjamin Meyer; Abdullah Assiri; Malak Al-Masri; Mohamed Farah; Katja Steinhagen; Erik Lattwein; Jaffar A Al-Tawfiq; Ali Albarrak; Marcel A Müller; Christian Drosten; Ziad A Memish
Journal:  J Clin Microbiol       Date:  2015-07-08       Impact factor: 5.948

Review 3.  Fast vaccine design and development based on correlates of protection (COPs).

Authors:  Cécile van Els; Siri Mjaaland; Lisbeth Næss; Julia Sarkadi; Eva Gonczol; Karen Smith Korsholm; Jon Hansen; Jørgen de Jonge; Gideon Kersten; Jennifer Warner; Amanda Semper; Corine Kruiswijk; Fredrik Oftung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Engineered influenza virions reveal the contributions of non-hemagglutinin structural proteins to vaccine mediated protection.

Authors:  Zhaochen Luo; Alanson W Girton; Brook E Heaton; Nicholas S Heaton
Journal:  J Virol       Date:  2021-03-03       Impact factor: 5.103

Review 5.  Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Authors:  Annette Fox; Kylie M Quinn; Kanta Subbarao
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

Review 6.  Inactivated influenza virus vaccines: the future of TIV and QIV.

Authors:  Michael Schotsaert; Adolfo García-Sastre
Journal:  Curr Opin Virol       Date:  2017-05-12       Impact factor: 7.090

7.  Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection.

Authors:  Maryna C Eichelberger; Arnold S Monto
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

8.  Evaluation of correlates of protection against influenza A(H3N2) and A(H1N1)pdm09 infection: Applications to the hospitalized patient population.

Authors:  Joshua G Petrie; Emily T Martin; Rachel Truscon; Emileigh Johnson; Caroline K Cheng; E J McSpadden; Ryan E Malosh; Adam S Lauring; Lois E Lamerato; Maryna C Eichelberger; Jill M Ferdinands; Arnold S Monto
Journal:  Vaccine       Date:  2019-02-07       Impact factor: 3.641

9.  Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.

Authors:  Felix Broecker; Allen Zheng; Nungruthai Suntronwong; Weina Sun; Mark J Bailey; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

10.  Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.

Authors:  Innocent N Mbawuike; Robert L Atmar; Shital M Patel; David B Corry; Patricia L Winokur; Rebecca C Brady; Wilbur H Chen; Kathryn M Edwards; C Buddy Creech; Emmanuel B Walter; Sharon E Frey; Robert B Belshe; Johannes B Goll; Heather Hill; Wendy A Keitel
Journal:  Vaccine       Date:  2015-12-04       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.